# Study Evaluating EKB-569 in Advanced Non-Small Cell Lung Cancer

> **NCT00067548** · PHASE2 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 44 (actual)

## Conditions studied

- Non-Small-Cell Lung Carcinoma
- Carcinoma, Non-Small Cell Lung
- Lung Neoplasms

## Interventions

- **DRUG:** EKB-569

## Key facts

- **NCT ID:** NCT00067548
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** 2005-01
- **Final completion:** 2005-01
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2009-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00067548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00067548, "Study Evaluating EKB-569 in Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00067548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*